1. Home
  2. IRMD vs AVLN Comparison

IRMD vs AVLN Comparison

Compare IRMD & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iRadimed Corporation

IRMD

iRadimed Corporation

HOLD

Current Price

$94.78

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$28.59

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IRMD
AVLN
Founded
1992
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2014
2026

Fundamental Metrics

Financial Performance
Metric
IRMD
AVLN
Price
$94.78
$28.59
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$116.00
N/A
AVG Volume (30 Days)
113.2K
413.8K
Earning Date
05-01-2026
N/A
Dividend Yield
0.95%
N/A
EPS Growth
16.67
N/A
EPS
0.45
N/A
Revenue
$83,814,000.00
N/A
Revenue This Year
$12.38
N/A
Revenue Next Year
$11.31
N/A
P/E Ratio
$208.58
N/A
Revenue Growth
14.43
N/A
52 Week Low
$56.20
$24.90
52 Week High
$107.90
$33.32

Technical Indicators

Market Signals
Indicator
IRMD
AVLN
Relative Strength Index (RSI) 48.44 41.88
Support Level $90.12 $27.22
Resistance Level $97.63 $29.59
Average True Range (ATR) 3.12 1.94
MACD -0.51 0.21
Stochastic Oscillator 30.51 62.25

Price Performance

Historical Comparison
IRMD
AVLN

About IRMD iRadimed Corporation

iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: